Skip to main content

Table 3 Percent of patients who received first-line bevacizumab by selected patient characteristics

From: Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

Characteristic* Received first-line bevacizumab
(n = 110)
Unadjusted p-value#
  %  
Age (years)   0.007
< 55 41  
55-64 32  
65-74 30  
≥ 75 16  
ACE-27 Comorbidity Index (score)   0.831
None (0) 29  
Mild (1) 30  
Moderate (2) 35  
Severe (3) 34  
Race   0.403
Non-white 28  
White 33  
Gender   0.005
Female 41  
Male 26  
Insurance   0.005
Private 41  
Public 20  
Medicare + supplemental 32  
Veterans Administration 21  
Missing 21  
Health system   0.050
Fee-for-service 35  
Integrated health system 25  
Geographic region   0.003
West/Midwest 23  
Southern 35  
Atlantic 43  
Annual household income   0.127
< $20,000/year 25  
≥ $20,000/year 34  
Missing 30  
Diagnosis of metastatic disease   0.532
Stage IV at diagnosis 30  
Recurrence 35  
Did anyone mention that enrollment in a clinical trial might be an option for you?   0.152
Yes 38  
No 28  
Missing 35  
How often do you read books, magazines or newspapers?   0.111
Often 35  
Rarely 24  
Missing 26  
After talking with your doctors about chemotherapy, how likely did you think it was that chemotherapy would have side-effects or complications?   0.133
Likely 33  
Not likely 24  
Missing 30  
  1. *The composition of health systems in the categorization of fee-for-services vs. integrated health systems has been previously described [8]. Comorbidity was calculated using the Adult Comorbidity Evaluation-27 (ACE-27) index [11]. The cardiovascular comorbidities were collected as a part of the ACE-27. #Unadjusted p-values for aggregate variable effects (type 3 Wald statistics).